NCT03095248View on ClinicalTrials.gov

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Neurofibromatosis 2Vestibular SchwannomaMeningiomaEpendymomaGlioma
Interventions
DRUG

Selumetinib

Continuous twice daily dosing; oral agent

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER